Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Assay Drug Dev Technol ; 3(4): 385-92, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16180993

RESUMEN

Hepatitis C virus (HCV) encodes a viral protease, nonstructural (NS)3/4A, that is critical for virus maturation. Although NS3/4A has emerged as a promising target for anti-HCV drug discovery, no anti-HCV therapy has succeeded yet based on inhibition of NS3/4A. We have previously shown that EG(delta4AB)SEAP, a reporter consisting of enhanced green fluorescent protein (EG), the NS3-NS4A protease decapeptide recognition sequence (delta4AB), and secreted alkaline phosphatase (SEAP), is an efficient reporter for reflecting NS3/4A proteolytic activity inside cells. In this study, we describe the generation and characterization of a stable cell line, 293EEG(delta4AB)SEAP-NS3/4A, which constitutively expresses EG(delta4AB)SEAP reporter protein and NS3/4A protease. The reporter assay is validated with the compound BILN 2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease. Additionally, we show here that this cell line allows screening for NS3/4A protease activity of living cells in 96-well plate format, with a Z factor >0.6. Thus, this cell-based assay may be used for high-throughput screening of chemical libraries.


Asunto(s)
Proteínas Portadoras/antagonistas & inhibidores , Hepacivirus/efectos de los fármacos , Inhibidores de Serina Proteinasa/farmacología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas Virales/antagonistas & inhibidores , Fosfatasa Alcalina/genética , Fosfatasa Alcalina/metabolismo , Antivirales/farmacología , Carbamatos/farmacología , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Línea Celular , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Genes Reporteros , Proteínas Fluorescentes Verdes/genética , Hepacivirus/crecimiento & desarrollo , Humanos , Péptidos y Proteínas de Señalización Intracelular , Compuestos Macrocíclicos/farmacología , Plásmidos , Quinolinas/farmacología , Proteínas Recombinantes de Fusión/metabolismo , Conteo por Cintilación/métodos , Inhibidores de Serina Proteinasa/análisis , Tiazoles/farmacología , Transfección , Proteínas no Estructurales Virales/genética , Proteínas no Estructurales Virales/metabolismo , Proteínas Virales/genética , Proteínas Virales/metabolismo
2.
J Virol Methods ; 116(1): 27-33, 2004 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-14715304

RESUMEN

Hepatitis C virus (HCV) encodes a polyprotein that needs to be processed proteolytically by cellular and viral proteases into mature functional proteins. One of the viral proteins, NS3/4A, has serine protease activity that is critical for virus maturation. The generation and characterization of an engineered HCV replicon cell line (Ava5) is described which constitutively expresses EGdelta4AB)SEAP reporter protein and the cell line was designated as Ava5-EG(delta4AB)SEAP. EG(delta4AB)SEAP is a fusion protein in which Enhanced Green Fluorescent Protein (EGFP) was fused to SEcreted Alkaline Phosphatase (SEAP) through the NS3/4A protease decapeptide recognition sequence, delta4AB, which spans the NS4A and NS4B junction region. The secretion of SEAP into culture medium has been shown to depend on the cleavage of delta4AB by HCV NS3/4A protease. It is demonstrated that the amount of NS3/4A in Ava5-EG(delta4AB)SEAP cells correlated well with the copy numbers of HCV subgenomic RNA. It is also shown that replication of HCV subgenomic RNA inside cells is reflected by the alkaline phosphatase (SEAP) levels in culture medium. SEAP activity in the culture medium of Ava5-EG(delta4AB)SEAP was approximately 50-fold higher than the parental Ava5 cells. Ava5-EG(delta4AB)SEAP was validated as a drug screening system since several known HCV inhibitors were shown to reduce SEAP activities in culture media of Ava5-EG(delta4AB)SEAP cells. In conclusion, Ava5-EG(delta4AB)SEAP cells can be used to monitor HCV sub-genomic replication and the assay can be readily adapted to high throughput screening format to identify prospective anti-HCV drugs.


Asunto(s)
Antivirales/farmacología , Evaluación Preclínica de Medicamentos/métodos , Hepacivirus/efectos de los fármacos , Replicón , Replicación Viral/efectos de los fármacos , Fosfatasa Alcalina/genética , Línea Celular , Medios de Cultivo/química , Proteínas Fluorescentes Verdes , Hepacivirus/crecimiento & desarrollo , Humanos , Interferón-alfa/farmacología , Interferón gamma/farmacología , Proteínas Luminiscentes , Proteínas Recombinantes de Fusión/metabolismo , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismo , Inhibidores de Serina Proteinasa/farmacología , Clorometilcetona de Tosilfenilalanila/farmacología , Proteínas no Estructurales Virales/genética , Proteínas no Estructurales Virales/fisiología , Proteínas Virales/genética , Proteínas Virales/fisiología
3.
Gastroenterology ; 124(1): 80-90, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12512032

RESUMEN

BACKGROUND & AIMS: Hepatitis B virus (HBV) evolves rapidly in patients with chronic hepatitis B, and HBV variation may trigger acute exacerbation. To study this relationship, we investigated full-length viral sequences before, during, and after exacerbation. METHODS: We prospectively studied 14 patients with exacerbation of hepatitis B, either spontaneously (n = 4) or after receiving various medical interventions (n = 10), and measured their serum alanine aminotransferase (ALT) and HBV DNA levels monthly. Full-length HBV genomes at baseline, at the peak of serum viral load, at ALT peak, and after ALT peak were obtained by polymerase chain reaction, sequenced, and compared. Replication activities of serial HBV variants were assayed by in vitro transfection. RESULTS: Serum viral load was increased in all exacerbations. Viral peak preceded ALT peak in 13 (93%) of the 14 patients. At virologic peak, 12 patients (86%) harbored viral genome identical to the corresponding baseline genome. At and after ALT peak, 9 (64%) and 7 (50%) of the viral genomes remained identical to baseline, respectively. Mean nucleotide change per genome was 0.2 at virologic peak but increased to 4.4 and 8.1 at and after ALT peak, respectively. The replication potential of the viral variant that emerged during or after exacerbation was equivalent to that at baseline. CONCLUSIONS: Most exacerbations were preceded by an upsurge of serum HBV identical to the preexisting HBV strain. After exacerbation, about half of the patients were repopulated by a different viral variant, which was likely a result of immune selection.


Asunto(s)
Genoma Viral , Virus de la Hepatitis B/genética , Hepatitis B/fisiopatología , Adulto , Alanina Transaminasa/sangre , Sustitución de Aminoácidos , Secuencia de Bases/genética , Portador Sano , Femenino , Variación Genética/fisiología , Hepatitis B/sangre , Hepatitis B/virología , Antígenos e de la Hepatitis B/análisis , Virus de la Hepatitis B/fisiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Carga Viral , Replicación Viral
4.
Cancer Res ; 62(15): 4346-51, 2002 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-12154039

RESUMEN

The CAG polymorphism in exon 1 of the androgen receptor (AR) gene has been shown associated with the development of human male hepatocellular carcinoma (HCC) with the shorter AR alleles conferring a higher risk. However, the significance of AR-CAG repeats in female hepatocarcinogenesis remains to be addressed. In this study, seventy-six pairs of female HCCs and corresponding nontumorous tissues were collected, and 180 cirrhotic nodules were microdissected from 7 cirrhotic livers. The clonality status, functional AR alleles, and CAG repeat number of each sample were determined by AR methylation analysis. In a total of 44 monoclonal HCCs, the mean of CAG repeats in the active alleles was significantly longer than that in the inactive alleles (22.0 +/- 2.8 versus 20.7 +/- 3.6; P = 0.047). When we divided HCCs into hepatitis B virus-positive [HBV(+)] and HBV(-) subgroups, the long AR allele dominance was found only in HBV(+) ones (P = 0.006 versus P = 0.923). Notably, the preference of long CAG repeat has also been found in the 100 monoclonal nodules (P = 0.013). For comparison of monoclonal nodules obtained from the same individual, a dominant long AR allele was found in 6 patients. The proportion of monoclonal cirrhotic nodules and HCCs expressing longer AR allele, 69 and 68%, are both significantly higher than 50%, the assumed value in normal liver (P < 0.001 for cirrhotic nodules and P = 0.005 for HCC). The dominance is again only prominent in HBV-infected HCCs [85% for HBV(+) HCC; P < 0.001 but 54% for HBV(-) HCC; P = 0.27]. The results indicated that in female hepatocarcinogenesis, hepatocytes expressing the longer AR allele seem to be favorably selected for autonomous growth and transformation, especially in synergy with HBV infection.


Asunto(s)
Alelos , Carcinoma Hepatocelular/genética , Virus de la Hepatitis B , Hepatitis B/complicaciones , Neoplasias Hepáticas/genética , Receptores Androgénicos/genética , Adulto , Anciano , Anciano de 80 o más Años , Desequilibrio Alélico , Carcinoma Hepatocelular/virología , Metilación de ADN , Femenino , Hepatitis B/genética , Humanos , Cirrosis Hepática/genética , Cirrosis Hepática/virología , Neoplasias Hepáticas/virología , Persona de Mediana Edad , Secuencias Repetitivas de Ácidos Nucleicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...